Leadership Team

Professor Plaas leads Apsynora Therapeutics with a relentless focus on translational medicine. His extensive background in bridging the gap between benchside discoveries and bedside applications forms the empirical foundation of our pipeline development. He oversees all strategic scientific directions, ensuring robust methodologies govern our preclinical endeavors.

Dr. Laas architecturally designs our clinical pathway strategies. With a stringent focus on empirical clinical data and regulatory alignment, she translates complex preclinical findings into viable, high-fidelity clinical trial designs, ensuring optimal asset positioning for subsequent phases.

Directing the empirical engine of Apsynora, Toomas oversees all preclinical assay development and validation. His rigorous approach to pharmacological profiling and toxicology ensures that only the most robust, high-confidence compounds advance toward IND enablement.